GEN-MKT-18-7897-A
Aug 20, 2015 | Blogs, Life Science Research, Proteomics | 0 comments
A recent study by Katy Williams (UCSF), Christie Hunter (SCIEX), and Andrew Olsen (Advaita) used the iPathwayGuide within the OneOmics cloud computing environment to help understand how placental development can go awry during certain pregnancy complications such as pre-eclampsia.
In this pilot study, the researchers studied cytotrophoblast differentiation. Cytotrophoblasts are the cells that are mainly responsible for establishing an anchor between the developing embryo and placenta with the uterine wall. The researchers compared cytotrophoblasts from the primary culture at both 2nd trimester and full term. SWATH proteomics data acquired using a SCIEX TripleTOF® 6600 System were analyzed in OneOmics using iPathwayGuide to identify differentially regulated proteins and their associated pathways, biological processes, and molecular functions. The proteomics data were then compared with RNASeq transcriptomics data acquired using an Illumina HiSeq System. Both the proteomics data and transcriptomics data were correlated using the OneOmics Platform and iPathwayGuide in the cloud. This meta-analysis allowed the researchers to discover common pathways and processes between the data sets as well as those only observed in the proteomic or transcriptomic datasets alone.
The pilot study helped to illuminate the biological significance of multiple proteins and pathways and provided an effective pipeline for taking raw data to biological answers.
See the complete study by viewing a 10 minute mini webinar. If you’d like to get a demo of the OneOmics Project, just comment below and we’ll be in touch.
In biopharmaceutical development, sequence variants (SV) are considered an inherent risk of producing complex proteins in living systems. Sequence variants are unintended changes to the amino acid sequence of a biotherapeutic and can be caused by errors in transcription or translation in the host cell, or cell culture and process conditions. Detailed analysis of SVs is important in process and product development to ensure the drug’s safety and efficacy. Even low‑level sequence variants can have significant implications for product quality, safety, and efficacy, making their accurate detection and characterization a critical requirement across development, process optimization, and regulatory submission.
CE‑SDS remains a cornerstone assay for characterizing fragmentation, aggregation, and product‑related impurities in therapeutic proteins. UV detection has been the long‑standing standard. However, it frequently struggles with baseline noise, limited sensitivity for minor fragments, and subjective integration.
At SCIEX, innovation doesn’t stop at instruments; it extends to how you interact with your LC-MS/MS or CE systems every day. That’s why we’re excited to introduce the SCIEX Now spring 2026 improvements: a set of meaningful enhancements shaped directly by your feedback.
Posted by
You must be logged in to post a comment.
Share this post with your network